



## INTENDED USE OF THE DEVICE

Device used to prepare intra-articular injections for symptomatic treatment of articular pain and mobility improvement.

### CONTRA-INDICATIONS

Do not administer to patients with ascertained hypersensitivity to one of the components, or suffering from serious disease such as cancer or infection in joint or in the treated area. The administration of the HA/PRP preparation to patients suffering from inflammatory joint diseases and autoimmune diseases such as rheumatoid arthritis or Bechterew disease is not recommended. The administration to children, pregnant or lactating women is not recommended.

### POSSIBLE SIDE EFFECTS

Blood puncture and injection may cause damage of the blood vessels and hematomas. When injected intra-articularly, local secondary inflammatory reactions may occur at the site of injection. This may result in temporary pain, feeling of heat, redness and swelling in the joint or area treated with the HA/PRP preparation. Icepacks application in the minutes following the injection, or local analgesic treatment the day following the injection may decrease these inconveniences. There have also been occasional reports of hyper-sensitivity, including, rarely, anaphylaxis. The administration of HA was also reported to provoke pronounced inflammatory reactions. Injection may lead to infection if general precautions for injection and asepsis are not respected.

CE 0086

Intellectual Property Rights (IPRs) as Core Assets [www.regenlab.com/patents](http://www.regenlab.com/patents)

## ORDERING INFORMATION

### CellularMatrix / BCT-HA-3

(Double Blister)

Ref: BCT-HA-3

3 BCT-HA tubes



### PRODUCT

# Quality

ISO 13485 Certified

Patented Innovations

+2 Million Patients treated

CE Certified

### PATIENT

# Safety

GMP Manufacturing

Class III Medical Devices

Non Pyrogenic - sterile

### A-PRP®

# Efficacy

Dedicated Kits for  
specific preparations

+ 170 published studies

### Patented by Regen Lab SA - CellularMatrix (PRP+HA)

U.S. patent US8945537,

U.S. patent US9517255,

European patent EP2544697B1

Canadian patent CA2789533C,

Chinese patent CN103079577B,

Australian patent AU2011225828B,

Japanese patent JP6076091,

Russian patent RU2614722,

Israeli patent IL221133

Regen Lab SA  
En Budron B2  
CH - 1052 Le Mont-Sur-Lausanne  
Switzerland  
Tel. +41(0)21 864 01.11 — Fax. +41(0)21 864 01.10  
[www.regenlab.com](http://www.regenlab.com)

BCTHA-EN-AMWC-V190319



## Natural HA Enriched by Your Platelet Growth Factors.



**regenlab®**

PRP® & CELL THERAPY SPECIALISTS

# A revolutionary innovation combining two treatment concepts in one for natural results.

**A-PRP: the patient's platelet concentrate prepared with CellularMatrix, provides an autologous reservoir of growth factors.**

**Platelets** are key factors in hard and soft tissue repair mechanisms <sup>1</sup>. They provide essential growth factors, such as FGF, PDGF, TGF-β, EGF, VEGF, IGF, which are involved in cell migration, differentiation and proliferation. The platelets are concentrated from the patient's own blood.

**Plasma** contains many factors essential for cell survival including nutrients, vitamins, hormones, electrolytes, growth factors (such as IGF and HGF), and proteins. Among the plasma proteins, the molecules vital for the coagulation process and for the fibrin polymer formation will serve as a scaffold for cell migration and new tissue generation.

- Stimulates cell differentiation and proliferation
- Triggers angiogenesis

**Hyaluronic Acid (HA) is the key molecule that has unique capacity in retaining water <sup>2,3,4</sup>**


- More than 25 years of clinical experience
- Major component of the extracellular matrix
- Binds water and creates volume
- Stimulates migration and proliferation of cells

## REFERENCES

1. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96.  
2. Cho JM, Lee YH, Baek RM, Lee SW. Effect of platelet-rich plasma on ultraviolet b-induced skin wrinkles in nude mice. J Plast Reconstr Aesthet Surg 2011;64:e31-9.  
3. Laurent TC, Frase Jr. Hyaluronan. FASEB J1992;6:2397-404  
4. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology. 2003 Dec;13(12):105R-115R.

Immediate formation, in one easy step, of a cell-friendly HA network in which platelets are dispersed, using a system which is specifically approved for preparation of the HA / A-PRP association.

CellularMatrix is a Medical Device that contains 2 ml of natural, non-crosslinked, HA at a concentration of 20 mg / ml (40 mg total), in addition to the thixotropic cell-separation gel and the sodium citrate anticoagulant solution.



Both HA and the Patient's A-PRP prepared with CellularMatrix have excellent safety profiles in clinical practice.



The Biobridge Foundation is Regen Lab's Educational Partner.